Loading..

Eagle Pharmaceuticals, Inc. (EGRX) Report Analysis

Corporate Events

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Comp Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2500 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000E Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Microcap Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) drop...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value-Defensive Index

Positive

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) adde...

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) added to Russell 2000 Dynamic Index

Positive

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) com...

2022-06-09 00:00:00

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareho...

Positive

Eagle Pharmaceuticals, Inc. Announces Submissio...

2022-06-01 11:01:00

Eagle Pharmaceuticals, Inc. announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group with whom Eagle entered into a li...

Neutral

Eagle Pharmaceuticals, Inc. Presents at William...

2022-05-28 20:26:00

Eagle Pharmaceuticals, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 09:40 AM. Venue: Loews Chicago H...

Neutral

Eagle Pharmaceuticals, Inc. to Report Q1, 2022 ...

2022-04-28 20:30:00

Eagle Pharmaceuticals, Inc. announced that they will report Q1, 2022 results Pre-Market on May 09, 2022

Neutral

Eagle Pharmaceuticals, Inc., Q1 2022 Earnings C...

2022-04-28 20:30:00

Eagle Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Acacia Pharma Group plc, Eagle Pharmaceuticals,...

2022-03-28 08:00:00

To discuss proposed transaction of Acacia Pharm

Positive

Eagle Pharmaceuticals, Inc. Announces Commercia...

2022-02-01 11:50:00

Eagle Pharmaceuticals, Inc. announced the commercial availability of its novel product PEMFEXY™ (pemetrexed for injection). A branded alternat...

Positive

Eagle Pharmaceuticals, Inc. on Track to Support...

2022-01-31 11:50:00

Eagle Pharmaceuticals, Inc. announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, with whom it entered into a licens...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Positive

Eagle Pharmaceuticals, Inc. Receives 180 Days o...

2021-12-29 16:24:00

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days o...

Negative

Judith Ng-Cashin Separates as Executive Vice Pr...

2021-12-27 15:51:00

On December 27, 2021, Judith Ng-Cashin separated as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc., or the Com...

Positive

Eagle Pharmaceuticals, Inc. Receives FDA Approv...

2021-12-15 18:54:00

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug appli...

Neutral

Eagle Pharmaceuticals, Inc. Presents at Piper S...

2021-11-22 15:06:00

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, Unit...

Neutral

Eagle Pharmaceuticals, Inc. Presents at Piper S...

2021-11-22 11:50:00

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers...

Neutral

Tranche Update on Eagle Pharmaceuticals, Inc. (...

2021-11-09 16:22:00

From July 1, 2021 to September 30, 2021, the company has repurchased 158,680 shares, representing 1.21% for $8.27 million. With this, the comp...

Neutral

Eagle Pharmaceuticals, Inc. to Report Q3, 2021 ...

2021-10-28 21:05:00

Eagle Pharmaceuticals, Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 09, 2021

Neutral

Eagle Pharmaceuticals, Inc., Q3 2021 Earnings C...

2021-10-28 21:05:00

Eagle Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

Eagle Pharmaceuticals, Inc. Announces Executive Changes

2021-10-01 12:36:00

Effective as of September 27, 2021, David Pernock was appointed as Executive Vice President, Operations of Eagle Pharmaceuticals, Inc., or the...

Neutral

Eagle Pharmaceuticals, Inc. Presents at Morgan ...

2021-09-01 21:00:00

Eagle Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:00 PM. Venue: New Windsor, Uni...

Neutral

Eagle Pharmaceuticals, Inc. Presents at Cantor ...

2021-09-01 21:00:00

Eagle Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM. Venue: New York, United States. Speake...

Positive

Eagle Pharmaceuticals, Inc. Wins Vasopressin Pa...

2021-08-31 16:31:00

Eagle Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product...

Neutral

Eagle Pharmaceuticals, Inc. Announces Licensing...

2021-08-25 10:50:00

Eagle Pharmaceuticals, Inc. announced that it has entered into a worldwide licensing agreement with Combioxin SA for the commercial rights to ...

Neutral

Eagle Pharmaceuticals, Inc. - Special Call

2021-08-25 10:50:00

Eagle Pharmaceuticals, Inc. - Special Call

Neutral

Tranche Update on Eagle Pharmaceuticals, Inc. (...

2021-08-09 17:20:00

From April 1, 2021 to June 30, 2021, the company has repurchased 70,290 shares, representing 0.53% for $2.87 million. With this, the company h...

Neutral

Eagle Pharmaceuticals, Inc. Announces Licensing...

2021-08-09 10:45:00

Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (‘AOP Orphan’) for t...

Neutral

Eagle Pharmaceuticals, Inc., Q2 2021 Earnings C...

2021-07-28 20:30:00

Eagle Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

Eagle Pharmaceuticals, Inc. to Report Q2, 2021 ...

2021-07-28 20:30:00

Eagle Pharmaceuticals, Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 09, 2021

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Comp Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Comp Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2500 Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2500 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000E Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000E Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Microcap Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Microcap Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Value Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Value Index

Negative

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value-Defensive Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value-Defensive Index

Positive

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) added to Russell 2000 Dynamic Index

2022-06-24 00:00:00

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) added to Russell 2000 Dynamic Index

Positive

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders.

2022-06-09 00:00:00

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders for €89.8 million on March 27, 2022. Under the terms of the transaction, Eagle Pharmaceuticals will issue €0.68 in cash and 0.0049 New Eagle Shares for the acquisition. The cash portion of the consideration represents approximately 75% of the total consideration, and the New Eagle Shares that Acacia Shareholders would receive represent approximately 25% of the total consideration. The cash consideration payable by Eagle under the terms of the proposed transaction is expected to be financed by existing cash resources of Eagle. The remaining consideration payable by Eagle is expected to be paid in shares of Eagle common stock. The terms of the proposed transaction also provide for Eagle to guarantee approximately €25 million of debt within the Acacia Pharma group. Transaction is subject to approval of Acacia Pharma’s shareholders, the sanction of the Scheme by the court. The Acacia Board believes that the proposed transaction represents the best option for Acacia Shareholders to maximize the value of their shares, and therefore unanimously recommends the proposed transaction. As of May 19, 2022, shareholders of Acacia approved the transaction. Transaction is expected to be completed between the middle of May 2022 and June 30, 2022. Scheme is expected to becoming effective no later than June 30, 2022. On June 7, 2022, the High Court of Justice of England and Wales has sanctioned the Scheme for the arrangement. Accordingly, the Scheme will become effective upon the court order being delivered to the registrar of companies, which is expected to take place on June 9, 2022. The scheme is anticipated to be an attractive opportunity to potentially accelerate Eagle’s existing growth strategy and further its advantage in acute care. Christian Hodneland, Eugene Kim and Ty Weston of William Blair & Company, L.L.C. acted as financial advisor to Eagle Pharmaceuticals. Kevin Costantino, Rupert Hill, Dean Rodrigues and James Warr of Greenhill & Co. International LLP and Gil Bar-Nahum of Jefferies International Limited acted as financial advisor to Acacia Pharma. Cooley (UK) LLP and Nautadutilh acted as legal advisor to Eagle Pharmaceuticals. Sullivan & Cromwell LLP (UK) and Eubelius CVBA acted as legal advisor to Acacia Pharma. Equiniti acted as registrar of Acacia and American Stock Transfer & Trust Company LLC acted as Eagle’s transfer agent. Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders on June 1, 2022.

Positive

Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker

2022-06-01 11:01:00

Eagle Pharmaceuticals, Inc. announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for landiolol, a short-acting, intravenous (“IV”), cardio-selective beta-1 adrenergic blocker. The submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter. Landiolol is an ultra-short-acting, cardio-selective, beta-1 adrenoceptor blocker, which reduces heart rate and has a minimal effect over cardiac contractility (inotropy). Landiolol is designed for use in emergency, critical care, and operating room settings. It is registered in several European countries for the treatment of tachycardic supraventricular arrhythmias and non-compensatory sinus tachycardia. Landiolol is already commercially available in Japan (Onoact®) and several European markets as RAPIBLOC®. Multiple clinical studies in these geographies demonstrate that landiolol is a safe and effective option for the rapid short-term control of tachyarrhythmias (Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs. 2018 Mar;78(3):377-388. doi: 10.1007/s40265-018-0883-9. PMID: 29470800.). A Type C meeting was held with FDA in July 2020, at which time AOP Health proposed a submission strategy in which it would provide summaries of pre-existing safety and efficacy data and a meta-analysis of published randomized controlled trials. The FDA tentatively agreed with this methodological approach and deemed data sets adequate to support a proposed NDA. The management of rapid heart rate (tachycardia) in critically ill patients can be quite complicated regardless of the underlying cause. Beta blockers, also known as beta-adrenergic blocking agents, are a class of drugs that lower heart rate by blocking the neurotransmitters norepinephrine and epinephrine from binding to receptors. These neurotransmitters contribute to the development of tachycardia. ß-1 receptor beta blockers are used frequently in critical care settings to manage tachycardia; however, the available ß-1 beta blockers in the U.S. can have the unwanted effects of decreasing the contractility, or muscle strength, of the heart, and of lowering blood pressure to a greater extent than landiolol. Landiolol is ultra-short acting, with a rapid on and off effect that allows clinicians to quickly control heart rate with minimal impact on blood pressure. In addition, with a ß1:ß2 ratio of 255:1, landiolol is the most cardioselective beta blocker, which the Company believes will result in the least potential impact on respiratory function among available ß-blockers. The Company believes that clinicians will welcome landiolol as a key therapeutic tool for the more precise management of tachycardia in the critical care setting. There are additional clinical settings for which landiolol has the potential to improve patient management. Enrollment in LANDI-SEP, a European clinical trial studying landiolol in patients with tachycardia and septic shock, is complete. Importantly, landiolol is also being studied in a pediatric population, for whom no intravenous beta-blocker drug products are approved in the U.S. for ventricular rate control. The FDA has tentatively agreed that this study could form the basis for proposed pediatric study plans for a future submission to FDA.

Neutral

Eagle Pharmaceuticals, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 09:40 AM

2022-05-28 20:26:00

Eagle Pharmaceuticals, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 09:40 AM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States. Speakers: Brian Joseph Cahill, Chief Financial Officer, Scott L. Tarriff, Founder, President, CEO & Director.

Neutral

Eagle Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

2022-04-28 20:30:00

Eagle Pharmaceuticals, Inc. announced that they will report Q1, 2022 results Pre-Market on May 09, 2022

Neutral

Eagle Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 09, 2022

2022-04-28 20:30:00

Eagle Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Acacia Pharma Group plc, Eagle Pharmaceuticals, Inc. - Special Call

2022-03-28 08:00:00

To discuss proposed transaction of Acacia Pharm

Positive

Eagle Pharmaceuticals, Inc. Announces Commercial Availability of PEMFEXY™

2022-02-01 11:50:00

Eagle Pharmaceuticals, Inc. announced the commercial availability of its novel product PEMFEXY™ (pemetrexed for injection). A branded alternative to ALIMTA®, Eagle’s PEMFEXY is a ready-to-use liquid with a unique J-code approved to treat nonsquamous non-small cell lung cancer and mesothelioma. In February 2020, Eagle received final approval from the U.S. Food and Drug Administration of its New Drug Application for PEMFEXY, following the settlement agreement of patent litigation with Eli Lilly and Company in December 2019. The agreement provided for a release of all claims by the parties and allows for an initial entry of PEMFEXY into the market (equivalent to approximately a three-week supply of current ALIMTA utilization) on February 1, 2022 and a subsequent uncapped entry on April 1, 2022. On October 1, 2020, PEMFEXY’s Healthcare Common Procedure Coding System code, or J-code, became effective.

Positive

Eagle Pharmaceuticals, Inc. on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker

2022-01-31 11:50:00

Eagle Pharmaceuticals, Inc. announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, with whom it entered into a licensing agreement in August 2021, has engaged with the U.S. Food and Drug Administration to obtain alignment on the content and format of the pre-clinical and clinical data required to support a new drug application seeking approval of Landiolol, a novel therapeutic, for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. In August 2021, Eagle entered into a licensing agreement with AOP Health, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to Landiolol in the United States. Landiolol is a short-acting, ultra-high selective beta-1 adrenoceptor blocker developed by AOP Health that has a selective effect on heart rate over cardiac contractility. Landiolol is available in two forms (20 mg/2ml concentrate, 300 mg powder) and is designed for use in emergency, cardiac critical care, operating room, and intensive care settings. It is registered in several European countries for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The drug uses a proprietary dosing algorithm to facilitate the administration. Landiolol is already commercially available in Japan (Onoact) and several European markets as RAPIBLOC.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Positive

Eagle Pharmaceuticals, Inc. Receives 180 Days of Marketing Exclusivity for Approved Vasopressin

2021-12-29 16:24:00

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application (“ANDA”) for vasopressin. In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company. An appeal of that decision remains pending.

Negative

Judith Ng-Cashin Separates as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc

2021-12-27 15:51:00

On December 27, 2021, Judith Ng-Cashin separated as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc., or the Company. The Company intends to initiate the search for a replacement immediately.

Positive

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Vasopressin

2021-12-15 18:54:00

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application for vasopressin. This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.

Neutral

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-22 11:50:00

Eagle Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Brian Joseph Cahill, Chief Financial Officer, Scott L. Tarriff, Founder, President, CEO & Director.

Neutral

Tranche Update on Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX)'s Equity Buyback Plan announced on March 17, 2020.

2021-11-09 16:22:00

From July 1, 2021 to September 30, 2021, the company has repurchased 158,680 shares, representing 1.21% for $8.27 million. With this, the company has completed the repurchase of 1,037,830 shares, representing 7.73% for $47.58 million under the buyback announced on March 17, 2020.

Neutral

Eagle Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-28 21:05:00

Eagle Pharmaceuticals, Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 09, 2021

Neutral

Eagle Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-28 21:05:00

Eagle Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

Eagle Pharmaceuticals, Inc. Announces Executive Changes

2021-10-01 12:36:00

Effective as of September 27, 2021, David Pernock was appointed as Executive Vice President, Operations of Eagle Pharmaceuticals, Inc., or the Company. He previously served as President and Chief Operating Officer of the Company since January 2017. On September 27, 2021, the Board of Directors, or the Board, appointed Scott Tarriff as President, effective immediately. In addition to his role as President, Mr. Tarriff will continue to serve as Chief Executive Officer. On September 27, 2021, the Board appointed Michael Moran as the Company's Executive Vice President, Chief Commercial Officer, effective immediately, in which position he will serve as the Company's principal operating officer. Mr. Moran, age 53, joined the Company in January 2016 as Vice President, Sales and was promoted to Executive Vice President, Sales, Business Development and Government Affairs in August 2019.

Neutral

Eagle Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:00 PM

2021-09-01 21:00:00

Eagle Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:00 PM. Venue: New Windsor, United States. Speakers: Brian Joseph Cahill, Chief Financial Officer, Scott L. Tarriff, Founder, President, CEO & Director.

Neutral

Eagle Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM

2021-09-01 21:00:00

Eagle Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM. Venue: New York, United States. Speakers: Brian Joseph Cahill, Chief Financial Officer, Scott L. Tarriff, Founder, President, CEO & Director.

Positive

Eagle Pharmaceuticals, Inc. Wins Vasopressin Patent Trial

2021-08-31 16:31:00

Eagle Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company. Eagle is first to file an Abbreviated New Drug Application (“ANDA”) referencing Vasostrict®, which had total U.S. sales of $786 million in 2020. In May 2018, Par sued Eagle for infringement of several patents. The trial was held in July 2021. The Court heard Par’s argument as to why Eagle’s proposed product would infringe its patents, as well as Eagle’s arguments as to why Par’s patents are both invalid and unenforceable.

Neutral

Eagle Pharmaceuticals, Inc. Announces Licensing Agreement with Combioxin SA

2021-08-25 10:50:00

Eagle Pharmaceuticals, Inc. announced that it has entered into a worldwide licensing agreement with Combioxin SA for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. Under the Agreement, Eagle will be solely responsible for further clinical development of CAL02 and will make an upfront payment, followed by additional payments upon achievement of development milestones, regulatory approval and based upon commercial sales. Eagle expects to invest $35 million to achieve interim results. These interim results are expected in the first half of 2023. CAL02 is designed to be an add-on therapy to antibiotics to neutralize virulence effectors. CAL02 consists of liposomes that capture and neutralize bacterial toxins produced by a broad range of Gram-positive and Gram-negative bacteria. Bacterial toxins play a critical role in severe, complicated, and resistant infections. They are known to dysregulate inflammation, cause organ damage and impede immune defense. Unlike traditional antibacterial drugs, CAL02 does not target bacteria directly. The first-in-human clinical trial results show a favorable safety profile when administered in combination with standard antibiotics to patients with severe community-acquired bacterial pneumonia (“CABP”) hospitalized in the intensive care unit (“ICU”). Furthermore, as compared to patients under placebo, patients who were treated with CAL02 presented a faster clinical improvement, including a significantly faster resolution of organ dysfunctions (as per Sequential Organ Failure Assessment score).

Neutral

Eagle Pharmaceuticals, Inc. - Special Call

2021-08-25 10:50:00

Eagle Pharmaceuticals, Inc. - Special Call

Neutral

Tranche Update on Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX)'s Equity Buyback Plan announced on March 17, 2020.

2021-08-09 17:20:00

From April 1, 2021 to June 30, 2021, the company has repurchased 70,290 shares, representing 0.53% for $2.87 million. With this, the company has completed the repurchase of 879,150 shares, representing 6.51% for $39.31 million under the buyback announced on March 17, 2020.

Neutral

Eagle Pharmaceuticals, Inc. Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

2021-08-09 10:45:00

Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (‘AOP Orphan’) for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The Company will support the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter. Landiolol is a short-acting, ultra-high selective beta-1 adrenoceptor blocker developed by AOP Orphan that has a selective effect on heart rate over cardiac contractility. Landiolol is available in two forms (20 mg/2ml concentrate, 300 mg powder) and is designed for use in emergency, cardiac critical care, operating room, and intensive care settings. It is registered in several European countries for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The drug uses a proprietary dosing algorithm to facilitate the administration. Under the terms of the agreement, Eagle will facilitate the U.S. regulatory pathway for the approval of Landiolol. In addition, Eagle will be responsible for the U.S. commercialization of the product upon approval. Landiolol, which has not previously been marketed in the U.S., is covered by several patents, and the Company anticipates five years of new chemical entity (“NCE”) exclusivity. Landiolol is already commercially available in Japan (Onoact®) and several European markets as RAPIBLOC®. A review of multiple clinical studies suggests that Landiolol is a useful option for the rapid short-term control of tachyarrhythmias (Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs. 2018 Mar;78(3):377-388. doi: 10.1007/s40265-018-0883-9. PMID: 29470800.). A Type C meeting was held with FDA in July 2020, at which time AOP Orphan proposed a submission strategy in which it would provide summaries of pre-existing safety and efficacy data and a meta-analysis of published randomized controlled trials. FDA tentatively agreed with this methodological approach and deemed data sets adequate to support a proposed NDA. The management of rapid heart rate (tachycardia) in critically ill patients can be quite complicated regardless of the underlying cause, which may include shock, arrhythmias, heart failure, and the postoperative setting. Beta blockers, also known as beta-adrenergic blocking agents, are a class of drugs that works by blocking the neurotransmitters norepinephrine and epinephrine from binding to receptors. These neurotransmitters contribute to the development of tachycardia. The ß-1 receptor beta blockers are used frequently in critical care settings to manage tachycardia; however, the available ß-1 beta blockers in the U.S. also can have the unwanted effects of decreasing the contractility, or muscle strength, of the heart, and of lowering blood pressure. Landiolol has the potential to become a cornerstone therapy in the management of these patients. It is ultra short acting, with a rapid on and off effect that allows clinicians to balance heart rate control and blood pressure more precisely. In addition, it predominantly affects heart rate without much effect on cardiac contractility and blood pressure. The Company believes that clinicians will welcome Landiolol as a key therapeutic tool for the more precise management of tachycardia in the critical care setting. There are additional clinical settings for which Landiolol has the potential to improve patient management. Enrollment is under way in Europe for a trial of Landiolol in patients with tachycardia and septic shock, and importantly, the product is also being studied in a pediatric population, for whom no beta-blocker drug products are approved in the U.S. for ventricular rate control. The U.S. FDA has tentatively agreed that this study could form the basis for initial pediatric study plan (“iPSP”) for a future submission to FDA.

Neutral

Eagle Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-07-28 20:30:00

Eagle Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

Eagle Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-07-28 20:30:00

Eagle Pharmaceuticals, Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 09, 2021

Fundamental Summary

At a high level, the metrics from Eagle Pharmaceuticals's Q1 financial report release provided many positive indicators. Their growth, value, and income factors indicate a well-executed and balanced strategy, which is generating exciting growth. This relative strength should allow Eagle Pharmaceuticals to continue to perform well even in a tough market. Therefore, they earned a total score of 79 out of 100 and a BUY recommendation.

Eagle Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 115.87 million compared to USD 41.25 million a year ago. Net income was USD 44.06 million compared to net loss of USD 0.421 million a year ago. Basic earnings per share from continuing operations was USD 3.47 compared to basic loss per share from continuing operations of USD 0.03 a year ago. Diluted earnings per share from continuing operations was USD 3.41 compared to diluted loss per share from continuing operations of USD 0.03 a year ago.

Business Description

Eagle Pharmaceuticals, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Sector Overview

Eagle Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Eagle Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 320.2 26.2% 70
Liabilities 104.2 34.8% 83
Price to Book 2.5 -32.5% 79
Cash & Equivalents 69.5 -28.8% 46
Equity 216.0 22.4% 73
EBITDA 71.6 802.8% 94
Total Revenues 246.2 43.5% 39
Parameter Value Change Score
Return on Equity 17.6 470.1% 53
Net Cashflow -35.7 -549.7% 63
Capital Expenditure -0.1 66.9% 97
Asset Turnover 0.8 25.4% 92
Free Cashflow 0.1 -96.3% 40

* All values are TTM

The below chart reflects Eagle Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Eagle Pharmaceuticals's peer average final assessment score stands on 72.0, Eagle Pharmaceuticals's score is 79.

  •  EGRX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Eagle Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Eagle Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 42.89
52W Low 41.26
52W High 56.9
5D MA 42.99
50D MA 45.23
200D MA 48.95
MACD -0.87
RSI 34.43
STOCH 35.75

Balance Sheet Analysis

Eagle Pharmaceuticals appears likely to maintain its strong balance sheet metrics and momentum going forward. In terms of liabilities, Eagle Pharmaceuticals published good numbers. Their reported liabilities were 104.2, representing a 34.8% change from the previous report. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 83. Also, Eagle Pharmaceuticals publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 2.5 and represents a -32.5% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. Consequently, their book value factors movement received a grade of 79. On the other hand, Cash & Equivalents, jumped out as looking problematic. Eagle Pharmaceuticals's management did a relatively poor job managing cash and cash equivalents, which now sit at 69.5 and represents a -28.8% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Its cash and cash equivalents movement, therefore, received a grade of 46. Therefore, it received a score of 75.

Parameter Value Change Score
Assets 320.2 26.2% 70
Liabilities 104.2 34.8% 83
Price to Book 2.5 -32.5% 79
Cash & Equivalents 69.5 -28.8% 46
Equity 216.0 22.4% 73
* All values are TTM

The below chart describes Eagle Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Eagle Pharmaceuticals received a balance sheet score of 75, the average of its peers stands on 71.0.

  •  EGRX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Eagle Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Eagle Pharmaceuticals's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as 71.6, which represents a 802.8% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 94. Also, In this filing, Eagle Pharmaceuticals reported a return on equity (ROE) ratio of 17.6, which represents a change of 470.1%. Its return factor metrics are even more remarkable when compared to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 53. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Eagle Pharmaceuticals management did an underwhelming job managing revenue efficiency this past period. Eagle Pharmaceuticals's revenue efficiency is 246.2 according to the metrics in the current filing, which represents a 43.5% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 39. Therefore, we scored its income statement a 78.

Parameter Value Change Score
EBITDA 71.6 802.8% 94
Total Revenues 246.2 43.5% 39
Return on Equity 17.6 470.1% 53
* All values are TTM

The below chart describes Eagle Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Eagle Pharmaceuticals received a income statement score of 78 , the average of its peers stands on 69.0.

  •  EGRX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Eagle Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Eagle Pharmaceuticals's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Eagle Pharmaceuticals recorded CapEx of -0.1, which represents 66.9% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 97. Also, Eagle Pharmaceuticals is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.8, representing a 25.4% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. The company's asset turnover movement, therefore, received a grade of 92. However, one discouraging result, Free Cash flow, stood out. Eagle Pharmaceuticals did a poor job related to generating and maintaining strong free cash flow this period, which stood at 0.1, representing a -96.3% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Its free cash flow movement, therefore, received a grade of 40. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 73.

Parameter Value Change Score
Net Cashflow -35.7 -549.7% 63
Capital Expenditure -0.1 66.9% 97
Asset Turnover 0.8 25.4% 92
Free Cashflow 0.1 -96.3% 40
* All values are TTM

The below chart describes Eagle Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Eagle Pharmaceuticals received a cash flow score of 73, the average of its peers stands on 70.0.

  •  EGRX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.